BPC + TB Blend

BPC-157 / TB-500 | Regenerative System

Technical card

System

Regenerative System
Type

Two-peptide blend
Components

BPC-157 │ TB-500
Form

Lyophilized vial
Purity

>98% per component by HPLC
Status

Active
Blend studies

Not available in current indexed literature

View Research Library

Access to the catalog is structured — not open by default.

How Access Works Already have access? Sign In

Technical card

System

Regenerative System
Type

Two-peptide blend
Components

BPC-157 │ TB-500
Form

Lyophilized vial
Purity

>98% per component by HPLC
Status

Active
Blend studies

Not available in current indexed literature

View Research Library

BPC + TB Blend Overview

The regenerative cascade is not a single event. It unfolds in phases — and each phase has distinct limiting factors. The BPC + TB Blend is built on this observation: two compounds, two mechanistically distinct points of entry, one research framework.

BPC-157 is investigated for its activity at the level of molecular signaling in damaged tissue: VEGFR2/eNOS vascular axis activation, fibroblast migration via FAK-paxillin phosphorylation, and pleiotropic downstream engagement of repair-associated transcription factors. In over 130 peer-reviewed publications, its primary research context is the signaling environment that initiates and sustains the repair response.

TB-500 is investigated for a different entry point: actin dynamics and cell motility. Through sequestration of G-actin and downstream MRTF-A nuclear translocation, TB-500 is studied in the context of how repair cells move toward and reorganize the site of injury. Its mechanism is not a repetition of BPC-157’s. It is the next step.

BPC + TB Blend Research Directions

Organized by compound — each body of evidence belongs to the individual peptide, not to the blend as a unit.

BPC-157:
– Musculoskeletal repair — tendon, ligament, muscle, and bone physiology in rodent preparations;
– Vascular function and angiogenesis — VEGFR2/eNOS axis, vasomotor tone, ischemia/reperfusion contexts;
– Gastrointestinal and mucosal protection — ulcer, colitis, fistula, and NSAID-induced mucosal damage models;
– Tendon fibroblast migration — FAK-paxillin phosphorylation and ECM remodeling;
– Neuroprotection and CNS modulation — spinal cord injury models, dopaminergic and serotonergic interactions;
– GH receptor potentiation — GHR upregulation in fibroblast models via JAK2 phosphorylation;
TB-500
– Cell migration — G-actin binding, MRTF-A nuclear translocation, SRF-dependent transcription;
– Musculoskeletal repair — tendon, muscle, and connective tissue models;
– Angiogenesis — endothelial cell migration and vascular tube formation via actin-dependent mechanisms;
– Anti-inflammatory signaling — downregulation of inflammatory mediators in injury models;
– Cardiac and vascular tissue — investigated in myocardial and vascular repair models;
– Wound healing — keratinocyte migration and dermal repair models;

Pathway

Description

BPC-157 primary target

VEGFR2 / eNOS / FAK-paxillin / ERK1/2 — vascular signaling and fibroblast activation

TB-500 primary target

G-actin / MRTF-A / SRF — cytoskeletal dynamics and directional cell migration

Pathway overlap

None identified between primary mechanisms

Research hypothesis

Sequential or parallel engagement of signaling (BPC-157) and motility (TB-500) entry points within the repair cascade

Evidence status

Individual compound literature: extensive (130+ publications BPC-157; documented cardiac, vascular, musculoskeletal models TB-500). Combined: no dedicated published study as of April 2026

BPC-157 and TB-500 each carry extensive individual preclinical literature. Published studies on this specific combination as a research unit are not available in the current indexed literature. The BPC + TB Blend was formulated on the basis of documented mechanistic complementarity — signaling entry (BPC-157) and motility entry (TB-500) — operating at distinct, non-overlapping points of the repair cascade. AXION documents what exists in the literature and what does not. This is the standard.

BPC + TB Blend Quality & Traceability

Every AXION compound is subject to analytical verification before release. Purity and traceability are not marketing attributes — they are part of the integrity of the research itself.

Certificate of Analysis

Available per lot on request. Issued per component.
Lot Traceability

Each vial carries a unique lot number.
QR Verification

QR code links to the COA for that specific lot.
HPLC Verified

>98% purity per component per lot.
Blend composition

Component ratios available in Product Access upon authorization.

Learn more about our verification process: Quality & Testing